Section 201 – Cannabis Research Review Board.
Effective 3/24/2022 26-61-201. Cannabis Research Review Board. (1) There is created the Cannabis Research Review Board within the department. (2) The department shall appoint, in consultation with a professional association based in the state that represents physicians, seven members to the Cannabis Research Review Board as follows: (a) three individuals who are medical research professionals; […]
Section 102 – Children with Heart Disease Support Restricted Account.
Effective 10/1/2016 26-58-102. Children with Heart Disease Support Restricted Account. (1) As used in this section, “account” means the Children with Heart Disease Support Restricted Account created in Subsection (2). (2) There is created in the General Fund a restricted account known as the “Children with Heart Disease Support Restricted Account.” (3) The account shall […]
Section 103 – Scope of telehealth practice.
Effective 5/5/2021 26-60-103. Scope of telehealth practice. (1) A provider offering telehealth services shall: (a) at all times: (i) act within the scope of the provider’s license under Title 58, Occupations and Professions, in accordance with the provisions of this chapter and all other applicable laws and rules; and (ii) be held to the same […]
Section 104 – Enforcement.
Effective 7/1/2022 26-60-104. Enforcement. (1) The Division of Professional Licensing created in Section 58-1-103 is authorized to enforce the provisions of Section 26-60-103 as it relates to providers licensed under Title 58, Occupations and Professions. (2) The department is authorized to enforce the provisions of: (a) Section 26-60-103 as it relates to providers licensed under […]
Section 105 – Study by Public Utilities, Energy, and Technology Interim Committee and Health Reform Task Force.
Effective 5/14/2019 26-60-105. Study by Public Utilities, Energy, and Technology Interim Committee and Health Reform Task Force. The Legislature’s Public Utilities, Energy, and Technology Interim Committee and Health Reform Task Force shall receive the reports required in Sections 26-18-13.5 and 49-20-414 and, during the 2019 interim, study: (1) the result of the reimbursement requirement described […]
Section 103 – Institutional review board — Approved study of cannabis, a cannabinoid product, or an expanded cannabinoid product.
Effective 3/25/2017 26-61-103. Institutional review board — Approved study of cannabis, a cannabinoid product, or an expanded cannabinoid product. (1) A person conducting an approved study may, for the purposes of the study: (a) process a cannabinoid product or an expanded cannabinoid product; (b) possess a cannabinoid product or an expanded cannabinoid product; and (c) […]
Section 105 – Standing prescription drug orders for an opiate antagonist.
Effective 5/4/2022 26-55-105. Standing prescription drug orders for an opiate antagonist. (1) Notwithstanding Title 58, Chapter 17b, Pharmacy Practice Act, a person licensed under Title 58, Chapter 17b, Pharmacy Practice Act, to dispense an opiate antagonist may dispense the opiate antagonist: (a) pursuant to a standing prescription drug order made in accordance with Subsection (2); […]
Section 106 – Overdose outreach providers.
Effective 5/9/2017 26-55-106. Overdose outreach providers. Notwithstanding Sections 58-1-501, 58-17b-501, and 58-17b-502: (1) an overdose outreach provider may: (a) obtain an opiate antagonist dispensed on prescription by: (i) a health care provider, in accordance with Subsections 26-55-104(2) and (3); or (ii) a pharmacist or pharmacy intern, as otherwise authorized by Title 58, Chapter 17b, Pharmacy […]
Section 107 – Opiate Overdose Outreach Pilot Program — Grants — Annual reporting by grantees — Rulemaking — Annual reporting by department.
Effective 1/1/2021 26-55-107. Opiate Overdose Outreach Pilot Program — Grants — Annual reporting by grantees — Rulemaking — Annual reporting by department. (1) As used in this section: (a) “Persons that are in a position to assist an individual who is at increased risk of experiencing an opiate-related drug overdose event”: (i) means the following […]
Section 108 – Coprescription guidelines.
Effective 5/4/2022 26-55-108. Coprescription guidelines. (1) As used in this section: (a) “Controlled substance prescriber” means the same as that term is defined in Section 58-37-6.5. (b) “Coprescribe” means to issue a prescription for an opiate antagonist with a prescription for an opiate. (2) The department shall, in consultation with the Physicians Licensing Board created […]